Pancreatic ductal adenocarcinoma contains an effector and regulatory immune cell infiltrate that is altered by multimodal neoadjuvant treatment.
about
Genetics and biology of pancreatic ductal adenocarcinomaClinical impact of chemotherapy to improve tumor microenvironment of pancreatic cancerFOXP3+ lymphocyte density in pancreatic cancer correlates with lymph node metastasisSystemic Immune Activity Predicts Overall Survival in Treatment-Naïve Patients with Metastatic Pancreatic Cancer.Role of immune cells in pancreatic cancer from bench to clinical application: An updated reviewChemoresistance in Pancreatic Cancer Is Driven by Stroma-Derived Insulin-Like Growth Factors.Novel directions in neoadjuvant therapy for pancreas adenocarcinoma.Strategies to relieve immunosuppression in pancreatic cancer.Regulatory T-cells from pancreatic lymphnodes of patients with type-1 diabetes express increased levels of microRNA miR-125a-5p that limits CCR2 expression.Targeting the microenvironment of pancreatic cancer: overcoming treatment barriers and improving local immune responses.Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas Cancer.Lymphocyte-to-monocyte ratio can predict mortality in pancreatic adenocarcinoma.T-cell programming in pancreatic adenocarcinoma: a review.CAR T-cell therapy for pancreatic cancer.IL17 producing γδT cells induce angiogenesis and are associated with poor survival in gallbladder cancer patients.Long-lived pancreatic ductal adenocarcinoma slice cultures enable precise study of the immune microenvironment.The pancreatic cancer microenvironment: an immunologic battleground.Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer.T-cell Localization, Activation, and Clonal Expansion in Human Pancreatic Ductal Adenocarcinoma.Focused ultrasound for immuno-adjuvant treatment of pancreatic cancer: An emerging clinical paradigm in the era of personalized oncotherapy.Prognostic Significance of Tumor-Infiltrating Lymphocytes in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Chemotherapy.Strategies for Increasing Pancreatic Tumor Immunogenicity.Phosphoinositide 3-Kinase Signaling Pathway in Pancreatic Ductal Adenocarcinoma Progression, Pathogenesis, and Therapeutics.Pancreatic Ductal Adenocarcinoma: A Strong Imbalance of Good and Bad Immunological Cops in the Tumor Microenvironment.Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options
P2860
Q26765438-BE0AA95F-38D0-481E-ACC3-B872F080105CQ28072263-C9BDBABA-5355-4476-96B0-91481E208598Q34142307-8620054E-5610-4267-8B1D-63E85B24725FQ36902015-C0DED249-760F-4A5D-B2FD-A0E2C87E9073Q37606102-52C09CDD-F3F8-47BD-97FE-40E9884ACD72Q37660216-F7D27774-501D-4559-9D5B-A948841FFF3EQ38357201-C4C74351-B8C5-48D2-9707-DEA8F59D33D5Q38445328-52697BA1-E31E-4298-AEA4-1C810B1897D4Q38650704-AAB6A1C6-8C06-4DB8-B861-52CD2A6565B3Q38667672-584D408B-F823-48B3-BA32-D428AC2334D9Q38808099-7D365B69-48C0-4B20-9D37-8AB8FF369FFDQ38952408-071B3E15-A100-45E0-A0B8-538AB9014EF3Q39026966-AD9DE902-7DEB-4EC2-87BA-0D46545CC74DQ39202440-66745832-7EBB-461C-B77E-68A57F0174A5Q40808689-6D4A2251-F49F-4BC2-BE8C-24ACD13957EDQ41251358-6DE1F21C-E75D-4C05-B306-428AC62F1761Q41970901-26A29181-1458-4922-BFF0-7648FDC73117Q42289841-2A0330F2-8443-486A-A06C-11E0C14DB571Q47726063-88FABB68-9DD9-4A2E-8FAC-2820B3981246Q47726467-D72F5A88-E6C1-4E6D-9C98-7BC6EB13DA92Q50118440-5696FE37-3BB2-4A81-BF78-8D6CC855D05AQ52691832-8598E91D-560F-4576-B24B-051828A975A7Q54980764-1910794C-757D-453C-8501-30FFEC0A98BEQ55080593-34875D80-4DD6-4B97-A7A1-80B4437D2E43Q56890107-3CF31826-D618-4646-996F-57723ECC4331
P2860
Pancreatic ductal adenocarcinoma contains an effector and regulatory immune cell infiltrate that is altered by multimodal neoadjuvant treatment.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Pancreatic ductal adenocarcino ...... timodal neoadjuvant treatment.
@ast
Pancreatic ductal adenocarcino ...... timodal neoadjuvant treatment.
@en
Pancreatic ductal adenocarcino ...... timodal neoadjuvant treatment.
@nl
type
label
Pancreatic ductal adenocarcino ...... timodal neoadjuvant treatment.
@ast
Pancreatic ductal adenocarcino ...... timodal neoadjuvant treatment.
@en
Pancreatic ductal adenocarcino ...... timodal neoadjuvant treatment.
@nl
prefLabel
Pancreatic ductal adenocarcino ...... timodal neoadjuvant treatment.
@ast
Pancreatic ductal adenocarcino ...... timodal neoadjuvant treatment.
@en
Pancreatic ductal adenocarcino ...... timodal neoadjuvant treatment.
@nl
P2093
P2860
P1433
P1476
Pancreatic ductal adenocarcino ...... timodal neoadjuvant treatment.
@en
P2093
Allison M Leahy
Cassian Yee
Jonathan G Sham
Kendall C Shibuya
Matthew M Yeh
Samuel H Whiting
Seth M Pollack
Stanley R Riddell
Venu G Pillarisetty
Vikas K Goel
P2860
P304
P356
10.1371/JOURNAL.PONE.0096565
P407
P577
2014-05-02T00:00:00Z